Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9NR23

UPID:
GDF3_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9NR23; Q8NEJ4

BACKGROUND:
The protein Growth/differentiation factor 3 (GDF3) is a critical growth factor involved in the regulation of early embryogenesis and adipose tissue equilibrium. It facilitates the development of the anterior visceral endoderm and mesoderm, as well as the establishment of body axis, through a receptor complex involving ACVR1B and TDGF1/Cripto. In the context of nutrient excess, GDF3 contributes to the regulation of adipose tissue homeostasis and energy balance through signaling pathways involving ACVR1C and TDGF1/Cripto.

THERAPEUTIC SIGNIFICANCE:
Given GDF3's association with significant developmental disorders, including Klippel-Feil syndrome 3 and various forms of Microphthalmia, its study is crucial for the development of targeted therapies. Understanding the role of Growth/differentiation factor 3 could open doors to potential therapeutic strategies, offering hope for patients affected by these genetic conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.